Interim report January-March 2019: The sixth quarter in row with improved results
- Strong organic growth and improved results
- New orthopaedic clinic opened in Stockholm
- Vårdsamverkan is investing in tools for analysing and optimising care chains
- A postponement of revenue in International has negatively affected the quarter
First quarter 2019
- Sales revenues increased to SEK 330.4 million (278.7)
- Organic growth increased to 17.4 percent (10.7)
- EBITDA increased to SEK 42.2 million (25.8). Excluding impact of IFRS 16, EBITDA increased to SEK 28.8 million (25.8)
- EBITDA margin increased to 12.8 percent (9.3). Excluding impact of IFRS 16, EBIDTA margin amounted to 8.7 percent (9.3)
- EBIT increased to SEK 21.4 million (19.3). Excluding impact of IFRS 16, EBIT increased to SEK 21.2 million (19.3)
- EBIT margin amounted to 6.5 percent (6.9). Excluding impact of IFRS 16, EBIT margin amounted to 6.4 percent (6.9)
- Result after tax (EAT) increased to SEK 15.1 million (14.0). Excluding impact of IFRS 16, EAT increased to SEK 15,6 million (14.0)
- Result per share amounted to SEK 0.18 (0.18). Excluding impact of IFRS 16, Result per share increased to SEK 0.19 SEK (0.18)
We have started the year with GHP’s best first quarter so far and once again we have a quarter with good organic growth. We have a strong culture of continuous development, with good momentum in each individual clinic. This is the foundation of the good quality and financial results. Furthermore, it attracts new employees and results in good growth.
When we have a good underlying business, it also creates scope for development and new initiatives. During the quarter we opened our new orthopaedic clinic at Gärdet in Stockholm. This is an initiative that initially entails some start-up costs, but it will make a positive contribution over time and will be appreciated by both our customers and our patients.
Our Nordic region segment continued to grow in the period and our revenues increased in all the submarkets of the segment. As we can see that the demand for high-quality specialist care continues to increase, we have continued to create more capacity at our clinics. In March yet another operating theatre was completed in Copenhagen and we managed to recruit more skilled specialists for our clinics during the first quarter. Another important area for our financial development is that choice of care and procurement processes are reasonably designed and encourage sound behaviour. Here we are actively working on supporting the development of structures through dialogue with the purchasers. This is long-term work but we have already seen that we can make a difference by focusing on this question.
Our International segment had an eventful quarter. Development of the four hospitals in the UAE continued in a positive direction, where the health care staff in the hospitals each day do important work to improve care and look after patients well. Our remuneration in the UAE is impacted amongst other things by in what quarter certain defined activities are carried out, which means that revenues can vary from quarter to quarter. During the first quarter there were somewhat fewer activities, which is also reflected in the revenues and results for the quarter. This means that later on in the year we will carry out all the more activities.
During the first few months of the year we have spent time explaining why it is so important that GHP is present in the United Arab Emirates. During the two years or so that we have run the hospitals we have been able, together with the authorities, to considerably develop the hospital care provided. For example, considerably more of the serious trauma cases that come to A&E survive and we have introduced modern obstetric care. For each and every one of the approximately 250,000 patients that seek care at the hospitals each year, GHP’s presence has only had a positive effect.
There is a great unmet need for health care in the region and we are convinced that GHP is in a good position to meet this need. We have therefore continued to concentrate on business development during the first quarter. Our business development team is focusing on securing new management contracts in the Middle East during 2019.
GHP’s third segment, Vårdsamverkan, continued to work during the quarter on helping insurance companies to offer patients an effective encounter with health care that is clearly coupled to high quality outcomes. We now have an efficient model where our way of working creates value for patients, insurance companies and GHP. Vårdsamverkan functions as an independent business of its own where we purchase care from both GHP’s own clinics and external clinics. During the first quarter we established tools to be able to further analyse and optimise care chains in a structured manner and we are constantly developing our digital offering so as to be able to meet insurance companies’ and patients’ needs.
It is now crucial that we continue to develop our segments to ensure that we realise the great potential which exists in each and every one of them and which creates a really strong whole.
23 April 2019
GHP Specialty Care AB (publ)
Queries should be addressed to:
Daniel Öhman, CEO, Tel: +46 708 55 37 07
Philip Delborn, CFO, Tel: +46 702 12 52 64
GHP is an internationally active health care provider that operates specialist clinics in a select number of diagnostic areas through the application of a business model that is unique in the health care industry, where leading doctors and medical staff become partners and shareholders. Each clinic specialises in a particular patient group, and this leads to increased efficiency and higher quality. This is the cornerstone of GHP’s business philosophy – “Quality through specialisation”. GHP shares are traded on the Small Cap list of Nasdaq Stockholm under the ticker symbol “GHP”.
GHP Specialty Care AB (publ) | Corp. ID No. 556757-1103
Södra Hamngatan 45 | SE-411 06 Gothenburg | Sweden
Tel +46-31 712 53 00 | Fax +46-31 313 13 21 | www.ghp.se
GHP Specialty Care AB (publ) is required to publish the information herein pursuant to the EU Market Abuse Regulation. This information was published, through the agency of the contact persons set out above, on 23 April 2019 at 08:00 a.m. CET.
This report has not been the subject of review by the company’s auditor.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.